Bespak has successfully reached the next stage of its strategy for nasal drug delivery through the signing of a partnership agreement with Lyfjathr-un Biopharmaceuticals, an Icelandic drug delivery company.
The collaboration will form a research and product development partnership for the development and commercialisation of new intellectual property.
Bespak and Lyfjathr-un aim to identify, characterise and develop novel proprietary formulations of drug candidates for delivery via the nasal passages.
Additionally, the partnership seeks to establish a pipeline of products with a focus on those formulations that extend pharmaceutical patents, improve bioavailability and/or improve the efficacy of defined drugs and pharmaceuticals.
Under the terms of the agreement, Bespak will provide marketing and drug delivery device technical support.
Lyfjathr-un will provide the facilities, technologies and personnel necessary for all pre-clinical work as well as for the clinical development and validation of new IPR.
The companies have already set up a project team, which has commenced work. The financial details of the partnership are not discloseable at this time.
Mark Throdahl, chief executive officer of Bespak, said: "This partnership is extremely exciting for us as we progress to the next stage of our nasal drug delivery programme.“
Professor Sveinbjsrn Gizurarson, ceo of Lyfjathrun Biopharmaceuticals, added: "We regard this agreement with Bespak as an important milestone. Through this Partnership Agreement and through Bespak's international experience and know-how in development and marketing, we feel that together we are now well positioned to take a leading role in the development of intranasally delivered drugs.“
Professor Gizurarson is an expert in the delivery of drugs through the nasal cavity and advises the US Food and Drug Administration in this specialist area.
For more information, visit www.bespak.com
